Tyrosine kinase inhibitor special issue
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy
Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study*
Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study*
Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours*
Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib
Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines*
European consensus document on mast cell tumours in dogs and cats